Login to Your Account

Renexxion advances former Aryx GI drug under new FDA guidance

By Michael Fitzhugh
Staff Writer

Thursday, November 17, 2016

A drug for gastrointestinal troubles shelved during Aryx Therapeutics Inc.'s 2011 demise is back in action at Renexxion LLC propelled by new FDA guidance setting aside the requirement for pre-approval cardiovascular safety outcome studies, the costly prospect of which scuttled the program's advancement at Aryx.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription